Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBNX Beta Bionics	$18.33 +5.0%	$15.10	$8.89 ▼ $24.50	$796.81M	N/A	530,013 shs	343,873 shs
EMBC Embecta	$14.21 -0.4%	$11.04	$9.20 ▼ $21.48	$831.14M	1.08	605,207 shs	562,980 shs
INGN Inogen	$7.99 +3.6%	$6.96	$5.70 ▼ $13.33	$216.05M	1.72	277,814 shs	208,535 shs
TNDM Tandem Diabetes Care	$12.24 +1.1%	$15.26	$9.98 ▼ $47.60	$827.06M	1.46	1.73 million shs	1.61 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBNX Beta Bionics	+2.35%	+1.10%	+17.59%	+16.72%	+1,744,999,900.00%
EMBC Embecta	-0.83%	+5.79%	+21.57%	+26.64%	+1.86%
INGN Inogen	-0.52%	+2.12%	+13.38%	+16.47%	-38.37%
TNDM Tandem Diabetes Care	+1.51%	+11.72%	-23.79%	-43.62%	-72.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	4.6933 of 5 stars	3.2	3.0	3.3	0.0	4.1	1.7	3.8
INGN Inogen	4.3173 of 5 stars	3.3	5.0	0.0	3.9	2.2	1.7	0.6
TNDM Tandem Diabetes Care	4.6208 of 5 stars	4.1	3.0	0.0	4.9	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBNX Beta Bionics	2.75	Moderate Buy	$22.56	23.05% Upside
EMBC Embecta	2.33	Hold	$19.00	33.71% Upside
INGN Inogen	2.50	Moderate Buy	$11.00	37.67% Upside
TNDM Tandem Diabetes Care	2.27	Hold	$22.47	83.55% Upside

Current Analyst Ratings Breakdown

Latest INGN, EMBC, BBNX, and TNDM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	TNDM Tandem Diabetes Care	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$10.35 ➝ $11.00
8/11/2025	TNDM Tandem Diabetes Care	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$75.00 ➝ $12.00
8/8/2025	TNDM Tandem Diabetes Care	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$53.00 ➝ $51.00
8/7/2025	TNDM Tandem Diabetes Care	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$59.00 ➝ $24.00
8/7/2025	TNDM Tandem Diabetes Care	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$30.00 ➝ $14.00
8/7/2025	TNDM Tandem Diabetes Care	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$20.00 ➝ $17.00
8/7/2025	TNDM Tandem Diabetes Care	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $13.00
8/7/2025	TNDM Tandem Diabetes Care	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $25.00
7/30/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $21.00
7/30/2025	BBNX Beta Bionics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$15.00 ➝ $17.00
7/16/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$13.00 ➝ $12.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBNX Beta Bionics	$78.02M	10.21	N/A	N/A	($5.72) per share	-3.20
EMBC Embecta	$1.12B	0.74	$3.30 per share	4.31	($12.80) per share	-1.11
INGN Inogen	$335.70M	0.64	N/A	N/A	$7.30 per share	1.09
TNDM Tandem Diabetes Care	$940.20M	0.88	N/A	N/A	$4.01 per share	3.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBNX Beta Bionics	-$54.76M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$78.30M	$1.43	9.94	4.63	0.80	7.58%	-23.40%	14.46%	N/A
INGN Inogen	-$35.89M	-$1.06	N/A	N/A	N/A	-7.58%	-13.77%	-8.52%	11/6/2025 (Estimated)
TNDM Tandem Diabetes Care	-$96.03M	-$3.09	N/A	N/A	N/A	-20.51%	-65.40%	-13.87%	11/5/2025 (Estimated)

Latest INGN, EMBC, BBNX, and TNDM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q3 2025	EMBC Embecta	$0.7720	$1.12	+$0.3480	$0.78	$278.15 million	$295.50 million
8/7/2025	Q2 2025	INGN Inogen	-$0.22	-$0.15	+$0.07	-$0.15	$90.40 million	$92.28 million
8/6/2025	Q2 2025	TNDM Tandem Diabetes Care	-$0.40	-$0.48	-$0.08	-$0.78	$238.39 million	$240.68 million
7/29/2025	Q2 2025	BBNX Beta Bionics	-$0.51	-$0.39	+$0.12	-$0.39	$19.73 million	$23.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.60	4.22%	N/A	41.96%	N/A
INGN Inogen	N/A	N/A	N/A	N/A	N/A
TNDM Tandem Diabetes Care	N/A	N/A	N/A	N/A	N/A

Latest INGN, EMBC, BBNX, and TNDM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	EMBC Embecta	quarterly	$0.15	5.79%	8/29/2025	8/29/2025	9/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBNX Beta Bionics	N/A	14.68	13.79
EMBC Embecta	N/A	2.47	1.78
INGN Inogen	N/A	3.03	2.67
TNDM Tandem Diabetes Care	2.32	2.44	1.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBNX Beta Bionics	N/A
EMBC Embecta	93.83%
INGN Inogen	89.94%
TNDM Tandem Diabetes Care	N/A

Insider Ownership

Company	Insider Ownership
BBNX Beta Bionics	N/A
EMBC Embecta	0.42%
INGN Inogen	1.46%
TNDM Tandem Diabetes Care	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBNX Beta Bionics	294	43.47 million	N/A	N/A
EMBC Embecta	2,100	58.49 million	58.24 million	Optionable
INGN Inogen	1,030	27.04 million	26.65 million	Optionable
TNDM Tandem Diabetes Care	2,650	67.57 million	66.29 million	Optionable

INGN, EMBC, BBNX, and TNDM Headlines

Recent News About These Companies

Charles Schwab Investment Management Inc. Sells 32,171 Shares of Tandem Diabetes Care, Inc. $TNDM

August 26 at 3:21 AM | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 7.4% Following Analyst Upgrade

August 24 at 2:19 AM | americanbankingnews.com

Tandem Diabetes Care Inc News (TNDM) - Investing.com

August 23 at 12:32 AM | investing.com

Tandem Diabetes Care, Inc. $TNDM Shares Purchased by Aberdeen Group plc

August 23 at 4:34 AM | marketbeat.com

Vanguard Group Inc. Reduces Holdings in Tandem Diabetes Care, Inc. $TNDM

August 23 at 3:35 AM | marketbeat.com

Tandem Diabetes Care (TNDM) Gets a Buy from RBC Capital

August 22, 2025 | theglobeandmail.com

Versor Investments LP Buys Shares of 30,500 Tandem Diabetes Care, Inc. $TNDM

August 22, 2025 | marketbeat.com

Algert Global LLC Purchases 119,784 Shares of Tandem Diabetes Care, Inc. $TNDM

August 22, 2025 | marketbeat.com

Citigroup Boosts Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $11.00

August 22, 2025 | americanbankingnews.com

Public Sector Pension Investment Board Raises Stock Position in Tandem Diabetes Care, Inc. $TNDM

August 19, 2025 | marketbeat.com

Sector Gamma AS Acquires New Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

August 17, 2025 | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by Brokerages

August 15, 2025 | marketbeat.com

Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 14, 2025 | tmcnet.com

Securities Fraud Investigation Into Tandem Diabetes Care, Inc. ...

August 14, 2025 | gurufocus.com

Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

August 14, 2025 | businesswire.com

Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money -- Contact Law Offices of Howard G. ...

August 14, 2025 | gurufocus.com

Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 14, 2025 | businesswire.com

Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 13, 2025 | businesswire.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up Following Insider Buying Activity

August 13, 2025 | marketbeat.com

5 Insightful Analyst Questions From Tandem Diabetes’s Q2 Earnings Call

August 13, 2025 | finance.yahoo.com

Tandem Diabetes Care: Strategic Growth Potential and Market Expansion Drive Buy Rating

August 13, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INGN, EMBC, BBNX, and TNDM Company Descriptions

Beta Bionics NASDAQ:BBNX

$18.33 +0.88 (+5.04%)

As of 04:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Embecta NASDAQ:EMBC

$14.21 -0.05 (-0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$14.21 0.00 (-0.01%)

As of 06:24 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Inogen NASDAQ:INGN

$7.99 +0.28 (+3.63%)

Closing price 04:00 PM Eastern

Extended Trading

$8.00 +0.00 (+0.06%)

As of 04:04 PM Eastern

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Tandem Diabetes Care NASDAQ:TNDM

$12.24 +0.13 (+1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$12.36 +0.13 (+1.02%)

As of 07:34 PM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time